At first glance, joining forces with BMS would bolster AZ\u2019s footprint in the U.S., while bringing over AZ\u2019s portfolio\u2014which the British company expects to surge<\/a> from $55.6 billion in 2025 revenue to $80 billion in 2030\u2014could easily add growth momentum to BMS.<\/p>\n In reality, an AZ-BMS merger would likely be a disaster. Combining the two drugmakers would trigger severe regulatory concerns and significant pipeline disruptions, not to mention cost numerous jobs, all while damaging the broader biopharma ecosystem and hurting patients.\u00a0\u00a0\u00a0<\/p>\n Acquisitions in the pharmaceutical industry thrive on strategic expansions\u2014entering a new therapeutic area, capturing a novel technology platform, growing geographically, or replacing a patent cliff. A union between AZ and BMS can yield a fraction of those benefits but represents the worst possible remedy for otherwise surmountable hurdles.\u00a0<\/p>\n To see what a legitimate \u201cbuying scale\u201d looks like, one need only go back eight years.\u00a0<\/p>\n Takeda\u2019s $62 billion acquisition<\/a> of Shire gave the Japanese pharma a major rare disease portfolio, with geographic expansion a central driver. When the deal was struck in 2018, Takeda lagged far behind<\/a> industry heavyweights, carrying a rather limited presence in the U.S. beyond just a couple of key products such as Entyvio. So, buying scale made sense for Takeda.\u00a0<\/p>\n In contrast, AstraZeneca does not have a U.S. void. Last year, the U.S. made up 43% of AZ\u2019s total product revenue, and the company has planned $50 billion<\/a> in U.S. investment by 2030, with some expansions already underway<\/a>. Rather than requiring a megadeal to break through in the U.S., AZ can simply grow its U.S. presence organically, just like its European peer Novartis is doing<\/a>.\u00a0<\/p>\n True, BMS is heavily U.S.-centric. But combining the two wouldn\u2019t unlock any new growth regions; instead, it would merely create an operationally overlapping monster in the same market.<\/p>\n The repetition problem goes beyond geographic footprint. While Shire provided Takeda with major diversification in rare diseases, the portfolio overlaps between AZ and BMS is jarring, setting the stage for antitrust nightmares and cannibalization.\u00a0\u00a0\u00a0<\/p>\n Among the most glaring roadblocks are checkpoint inhibitors. BMS and AZ market the only two commercial anti-CTLA-4 agents, Yervoy and Imjudo, and the two firms\u2019 anti-PD-(L)1 antibodies Opdivo and Imfinzi, target some of the same indications, too.<\/p>\n In cell therapy, AZ just pushed its BCMAxCD19 dual-targeting CAR-T therapy, AZD0120, into phase 3 tests in previously treated<\/a> and first-line<\/a> multiple myeloma, potentially threatening BMS\u2019 BCMA-directed Abecma.<\/p>\n Meanwhile, BMS\u2019 EGFRxHER3 antibody-drug conjugate, izalontamab brengitecan, represents a potential direct rival<\/a> to AZ\u2019s TROP2 ADC Datroway in breast cancer and lung cancer.\u00a0<\/p>\n The two firms\u2019 similar therapeutic interests\u2014and their sheer size\u2014scream antitrust concerns. To satisfy regulators and remove repetitive work, aggressive R&D reshuffling and program reprioritization are expected. Promising molecules would be shelved purely to satisfy corporate targets, reducing the number of therapies that could reach patients.\u00a0<\/p>\n Besides, even considering that BMS\u2019 chief medical officer, Cristian Massacesi, M.D., just joined<\/a> a year ago from a similar position at AZ, the years-long process of reconciling two massive drug R&D engines creates immense drag, causing delays in development timelines, which neither company can afford in a highly competitive environment.\u00a0<\/p>\n <\/a><\/p>\n AZ<\/p>\n AstraZeneca’s expected key phase 3 readouts from its second-quarter investor presentation on July 27. <\/a><\/p>\n BMS<\/p>\n BMS’ expected key data readouts from its second-quarter investor presentation on July 30.\u00a0 To justify the deal math, companies often point to cost synergies. Translation: layoffs, a signature move of megamergers. Back in 1998, the merger between Britain\u2019s Zeneca and Sweden\u2019s Astra, which created the AstraZeneca we know today, was expected to eliminate<\/a> around 6,000 jobs from the combined workforce. Compared to the rumored AZ-BMS deal, Zeneca\u2019s business, best known for cancer medicines, was considered more complementary to Astra\u2019s portfolio, which was led by the stomach acid drug Prilosec.\u00a0<\/p>\n As of 2025, AZ employed 96,100 employees worldwide and BMS had about 32,500 staffers.<\/p>\n In an industry that already saw over 22,000 job reductions<\/a> across major pharmas, combining AZ and BMS would only add to the pain, resulting in thousands of duplicate positions waiting to be eliminated across commercial, scientific, production and administrative divisions, plus potential site closures.\u00a0\u00a0<\/p>\n An AZ-BMS merger wouldn\u2019t just reshape the two companies involved; it would send shockwaves across the broader biopharma industry. A megadeal of this scale would deal a blow to the biotech M&A sentiment. When Big Pharma allocates $100 billion-plus toward consolidating megacap peers, it would signal a retreat to financial engineering, in which short-term cost synergies are preferred over more fine-tuned pursuit of genuine innovation. History has repeatedly shown that massive pharma consolidations rarely generate long-term value compared to targeted biotech acquisitions.<\/p>\n To cope with the imminent loss of exclusivity of Lipitor, Pfizer bought Wyeth in in 2009 for $68 billion, a deal that was marked by an easy revenue bump and massive job cuts<\/a>. However, beyond the immediate top-line growth, the merger didn\u2019t deliver<\/a> sustained R&D productivity, as the New York pharma would make a hostile takeover attempt<\/a> at AZ just five years later.\u00a0<\/p>\n Whether Takeda\u2019s move on Shire was worthwhile remains debatable, too. Despite its gain in commercial scale, the Japanese pharma was weighed down with heavy debts for a long time, significantly limiting its flexibility to pursue other biotech deals.<\/p>\n For AZ and BMS, both companies could far better achieve their strategic goals by deploying capital into biotechs and licensing deals.<\/p>\n AZ has already stated that it doesn\u2019t need M&A to reach its $80 billion revenue target by 2030. For a mature company like AZ, legacy commercial infrastructure does not add much value.\u00a0<\/p>\n The instant reaction from Jefferies analysts to yesterday’s reports chimes with this view. The analysts described themselves as \u201ca bit perplexed by the news.\u201d<\/p>\n \u201cOf course financial accretion can look good and maybe more cash generation would allow for more R&D,\u201d the analysts added in their note this morning. \u201cBut if there is one company that doesn’t need financial engineering, it’s AZ in our view.\u201d<\/p>\n
\n ![\"AZ\"\/](\"https:\/\/www.europesays.com\/britain\/wp-content\/uploads\/2026\/08\/astrazeneca_key_phase_3_readouts.jpg\")
<\/p>\n
\n (AstraZeneca)<\/p>\n
\n ![\"BMS\"\/](\"https:\/\/www.europesays.com\/britain\/wp-content\/uploads\/2026\/08\/bms_key_readouts.jpg\")
<\/p>\n
\n (Bristol Myers Squibb)<\/p>\n